Merck boosts Pfizer’s Covid antiviral advantage
Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel review beckons.
Daiichi could be rewarded for persisting with Vanflyta
A front-line trial yields a positive result two years after the drug got a US complete response letter.
Astra presses on with bispecifics
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
Mirati gets a combo coup
An adagrasib/Keytruda combo in front-line lung cancer looks promising, but patient numbers are small and Amgen looms large.
ASN 2021 – Glaxo’s daprodustat delivers
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
Centessa claims a place in the antitrypsin deficiency pipeline
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Idorsia sets itself up for failure
Cenerimod flunks a mid-stage lupus study, so Idorsia moves to go straight into phase 3. What can possibly go wrong?
Cortexyme and Lilly remind investors that Alzheimer’s failures happen
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
Lilly takes it to Biogen, and the Alzheimer’s events stack up
Lilly's remarkable decision to run a head-to-head trial of donanemab versus Aduhelm spells another big readout for the amyloid targeting space.
